Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.49 |
| ▸ | FABP7 | O15540 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 3/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570371 | 0.83 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL7121169 | 0.82 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL27587697 | 0.82 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL31222070 | 0.82 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL26932742 | 0.81 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1162471 | 0.81 | KMT2A (0.55) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29503798 | 0.80 | FABP5 (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28459608 | 0.80 | FABP5 (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29203790 | 0.79 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL17339044 | 0.79 | KMT2A (0.45) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116785450-A | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof | 伊缪诺金公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-116785451-A | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof | 伊缪诺金公司 | 2023-09-22 | — | — | CN | disclosed |
| CN-110366431-B | Maytansinoid derivatives with self-cleaving peptide linker and conjugates thereof | 伊缪诺金公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254603-A1 | CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| US-9688663-B2 | Crosslinking reagents, methods, and compositions for studying protein-protein interactions | Cell Mosaic, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160159777-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | CELLMOSAIC INC (US) | 2016-06-09 | — | — | US | disclosed |
| CN-102884077-B | Conjugated FVIII variants | 诺沃—诺迪斯克有限公司 | 2016-06-08 | — | — | CN | disclosed |
| US-20120322978-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | CELLMOSAIC, LLC | 2012-12-20 | — | — | US | disclosed |
| EP-2512523-A1 | LABELLED INTEGRIN BINDERS | GE Healthcare UK Limited (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| WO-2011109326-A2 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | HUANG YUMEI (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011073340-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-20100286024-A1 | Insulinotropic compounds and uses thereof | ACTIVOTEC SPP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-1943275-B1 | INSULINOTROPIC COMPOUNDS AND USES THEREOF | ACTIVOTEC SPP LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| EP-1943275-A1 | INSULINOTROPIC COMPOUNDS AND USES THEREOF | Activotec SPP Limited (GB) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007051987-A1 | INSULINOTROPIC COMPOUNDS AND USES THEREOF | ACTIVOTEC SPP LIMITED (GB) | 2007-05-10 | — | — | WO | disclosed |
| US-20030162185-A1 | Products comprising a support to which nucleic acids are fixed and their use as dna chips | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286024-A1 | Insulinotropic compounds and uses thereof | GLP1R, GPR119, IAPP | KMT2A 3871/4885FABP5 595/4885FABP7 946/4885 |
| US-20030162185-A1 | Products comprising a support to which nucleic acids are fixed and their use as dna chips | DNMT3A, TARBP1, DNMT3L | KMT2A 451/4885FABP5 560/4885FABP7 1425/4885 |
| US-20120322978-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | STUB1, PFN1, PFDN1 | KMT2A 2126/4885FABP5 12/4885FABP7 53/4885 |
| US-20120244074-A1 | LABELLED INTEGRIN BINDERS | ITGAV, ITGB6, ITGA2B | KMT2A 2759/4885FABP5 513/4885FABP7 435/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | KMT2A 2443/4885FABP5 3390/4885FABP7 3173/4885 |
| US-20160159777-A1 | CROSSLINKING REAGENTS, METHODS, AND COMPOSITIONS FOR STUDYING PROTEIN-PROTEIN INTERACTIONS | PBDC1, RCSD1, STUB1 | KMT2A 4097/4885FABP5 80/4885FABP7 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.